35 A post hoc analysis in the IBD sub-population from phase III clinical trials showed a trend of reduction in recurrent CDI in the bezlotoxumab group compared with placebo [27.2% absolute reduction with 95% confidence interval (CI) of −57.9 to 9.6]. 36 Fecal microbiota transplantation is emerging as a preferred treatment for multiple, recurrent CDIs in patients with underlying IBD.
← all excerpts
The interplay of <i>Clostridioides difficile</i> infection and inflammatory bowel disease.
1
—
—